Seer Business Summary

Seer, Inc. (SEER) is a life sciences technology company specializing in deep, unbiased proteomics through its proprietary Proteograph Product Suite. The company generates revenue through a dual-stream model consisting of product sales—comprising Proteograph instruments and recurring, high-margin consumable kits—and service fees from its Seer Technology Access Center (STAC). To navigate a constrained funding environment as of early 2026, Seer utilizes a Strategic Instrument Placement (SIP) program, which allows customers to leverage operating budgets for technology access, thereby lowering capital expenditure barriers. The business is primarily segmented into Product and Service divisions, reporting $16.6 million in total revenue for 2025 with an installed base of 82 instruments. Seer competes directly with Nautilus Biotechnology, Quanterix, and Standard BioTools, positioning itself as a high-throughput, unbiased solution that bridges the gap between traditional mass spectrometry and large-scale genomic data. Seer was co-founded by Chair and CEO Dr. Omid Farokhzad, a former Harvard Medical School professor and serial entrepreneur who previously founded BIND Therapeutics and Selecta Biosciences. The leadership team includes President and CFO David R. Horn, who brought over 20 years of investment banking experience from Morgan Stanley, and Chief Data Officer Serafim Batzoglou, a former machine learning lead at Insitro and Illumina. The company’s board of directors features prominent industry figures such as Dr. Robert Langer, a renowned MIT professor and Moderna co-founder, and Terry McGuire, founding partner of Polaris Partners. As of March 2026, the company is under active engagement from the Radoff-JEC Group, an activist investor cohort holding a 7.5% stake, which is advocating for strategic shifts to unlock value from Seer’s substantial $240.6 million cash reserve and proprietary proteoform profiling pipeline.